Language
English
Publication Date
1-1-2025
Journal
Helicobacter
DOI
10.1111/hel.70064
PMID
40993967
PMCID
PMC12460962
PubMedCentral® Posted Date
9-24-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Background: Helicobacter pylori eradication therapy typically consists of a combination of antibiotics and an antisecretory drug. Probiotics may be added to reduce side effects and possibly improve outcomes.
Materials and methods: We conducted a double-blind, randomized trial of pantoprazole plus either Lactobacillus reuteri (Gastrus) (high dose) or a matching placebo to assess the impact on the gut microbiota of H. pylori-positive adults. Fecal samples were collected at baseline and after one and 2 months for shotgun metagenomic sequencing.
Results: A total of 26 patients were recruited and completed therapy. L. reuteri was only detected in the group that received supplemental L. reuteri and only at the 1-month post-treatment interval. L. reuteri failed to colonize for long-term the gut, and challenge with L. reuteri failed to alter alpha-diversity (Shannon index) or beta-diversity (community ordination) metrics at any time point. Machine learning (PLS-DA) analysis identified the presence of L. reuteri as the most distinguishing feature at 1 month. No other taxa showed a significant difference between groups.
Conclusion: Short-term administration of pantoprazole and L. reuteri had no lasting effects on gut microbial composition. While L. reuteri transiently bloomed during supplementation, the overall gut microbiota showed resilience, returning to baseline shortly after therapy.
Keywords
Humans, Gastrointestinal Microbiome, Limosilactobacillus reuteri, Helicobacter Infections, Proton Pump Inhibitors, Female, Male, Middle Aged, Double-Blind Method, Adult, Pantoprazole, Probiotics, Helicobacter pylori, Feces, Aged, gut microbiota, Helicobacter pylori, Lactobacillus reuteri, probiotics, proton pump inhibitors
Published Open-Access
yes
Recommended Citation
Bibbò, Stefano; Ahlström, Gustav; Pes, Giovanni Mario; et al., "Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High-Dosage L. reuteri in H. pylori-Infected Adults" (2025). Faculty and Staff Publications. 5847.
https://digitalcommons.library.tmc.edu/baylor_docs/5847
Comments
Trial registration: Identifier: NCT03404440.